dextroamphetamine has been researched along with Pituitary Neoplasms in 4 studies
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.
Pituitary Neoplasms: Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the use of the central nervous system stimulant dextroamphetamine sulfate to regulate appetite and subsequent weight gain in children treated for craniopharyngioma." | 9.10 | The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. ( Krawiecki, N; Mason, PW; Meacham, LR, 2002) |
| "To examine the use of the central nervous system stimulant dextroamphetamine sulfate to regulate appetite and subsequent weight gain in children treated for craniopharyngioma." | 5.10 | The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. ( Krawiecki, N; Mason, PW; Meacham, LR, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mason, PW | 1 |
| Krawiecki, N | 1 |
| Meacham, LR | 1 |
| Ismail, D | 1 |
| O'Connell, MA | 1 |
| Zacharin, MR | 1 |
| DeLeo, V | 1 |
| Cella, SG | 1 |
| Camanni, F | 1 |
| Genazzani, AR | 1 |
| Müller, EE | 2 |
| Annunziato, L | 1 |
| Cocchi, D | 1 |
| di Renzo, G | 1 |
| Rossi, GL | 1 |
| Amoroso, S | 1 |
| Taglialatela, M | 1 |
1 trial available for dextroamphetamine and Pituitary Neoplasms
| Article | Year |
|---|---|
The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma.
Topics: Analysis of Variance; Body Mass Index; Central Nervous System Stimulants; Child; Child Behavior Diso | 2002 |
3 other studies available for dextroamphetamine and Pituitary Neoplasms
| Article | Year |
|---|---|
Dexamphetamine use for management of obesity and hypersomnolence following hypothalamic injury.
Topics: Adolescent; Central Nervous System Stimulants; Child; Child, Preschool; Craniopharyngioma; Dextroamp | 2006 |
Prolactin lowering effect of amphetamine in normoprolactinemic subjects and in physiological and pathological hyperprolactinemia.
Topics: Adenoma; Adult; Depression, Chemical; Dextroamphetamine; Dopamine; Female; Humans; Infusions, Parent | 1983 |
Reduced tuberoinfundibular dopaminergic neuronal function in rats after long-term withdrawal of estrogen treatment.
Topics: Animals; Dextroamphetamine; Dopamine; Estradiol; Estrogens, Conjugated (USP); Female; Hypothalamus; | 1986 |